What Challenges Exist in the Treatment of TRK Fusion-Positive Cancers?
Despite the promise of TRK inhibitors, challenges remain. Resistance to therapy is a significant concern, as tumor cells may develop mutations that render the inhibitors less effective. Additionally, not all patients with TRK fusion-positive cancers respond to treatment, highlighting the need for further research into the mechanisms of resistance and alternative therapeutic strategies. Access to testing and drugs also varies, which can impact treatment availability and outcomes.
